A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00457392
First received: April 4, 2007
Last updated: September 24, 2013
Last verified: September 2013
  Purpose

This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.


Condition Intervention Phase
Carcinoma, Non-Small Cell Lung
Drug: erlotinib
Drug: sunitinib
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Overall Survival (OS) [ Time Frame: Baseline to death or 28 days after last dose for the last participant ] [ Designated as safety issue: No ]
    Overall survival is the duration from assignment to study medication to death. For participants who are alive, overall survival is censored at the last contact.


Secondary Outcome Measures:
  • Progression-Free Survival (PFS) [ Time Frame: Baseline to disease progression or death due to any cause or 28 days after last dose ] [ Designated as safety issue: No ]
    Time in weeks from assignment to study medication to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was "Death").

  • Percentage of Participants With Objective Response (OR) [ Time Frame: Baseline to disease progression or discontinuation from study or 28 days after last dose ] [ Designated as safety issue: No ]
    Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.

  • Duration of Response (DR) [ Time Frame: Baseline to disease progression or death or discontinuation from study or 28 days after last dose ] [ Designated as safety issue: No ]
    Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.

  • One-year Survival Probability [ Time Frame: Baseline until death or until 28 days after last dose for the last participant ] [ Designated as safety issue: No ]
    The 1 year survival probability was defined as the probability of survival at one year after the date of the start of the study treatment based on the Kaplan Meier estimate.

  • EuroQol 5-Dimension Questionnaire (EQ-5D)- Health State Profile Utility Score [ Time Frame: Baseline and End of Treatment (EOT) or Withdrawal ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in total score range -0.594 to 1.000; higher score indicates better health state.


Enrollment: 960
Study Start Date: July 2007
Study Completion Date: December 2012
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: erlotinib
plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
Drug: sunitinib
Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
Active Comparator: 2 Drug: erlotinib
plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
Drug: placebo
Placebo daily by oral capsules in a continuous regimen

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with locally advanced/metastatic non-small cell lung cancer
  • Prior treatment with no more than 2 chemotherapy regimens including a platinum-based regimen

Exclusion Criteria:

  • Prior treatment with any receptor tyrosine kinase inhibitors, VEGF inhibitor (with the exception of bevacizumab) or other angiogenesis inhibitors
  • History of or known brain metastases
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00457392

  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site
Florence, Alabama, United States, 35630
Pfizer Investigational Site
Muscle Shoals, Alabama, United States, 35661
United States, Arizona
Pfizer Investigational Site
Scottsdale, Arizona, United States, 85258
United States, Arkansas
Pfizer Investigational Site
Hot Springs, Arkansas, United States, 71913
United States, California
Pfizer Investigational Site
Antioch, California, United States, 94531
Pfizer Investigational Site
Burbank, California, United States, 91505-4866
Pfizer Investigational Site
Downey, California, United States, 90241
Pfizer Investigational Site
Fresno, California, United States, 93720
Pfizer Investigational Site
La Jolla, California, United States, 92093-0987
Pfizer Investigational Site
La Jolla, California, United States, 92037
Pfizer Investigational Site
Montebello, California, United States, 90640
Pfizer Investigational Site
Pleasant Hill, California, United States, 94523
Pfizer Investigational Site
San Diego, California, United States, 92103
Pfizer Investigational Site
San Leandro, California, United States, 94578
Pfizer Investigational Site
Whittier, California, United States, 90606
United States, Connecticut
Pfizer Investigational Site
Fairfield, Connecticut, United States, 06824
United States, Florida
Pfizer Investigational Site
Brooksville, Florida, United States, 34613
Pfizer Investigational Site
Cocoa Beach, Florida, United States, 32931
Pfizer Investigational Site
Fort Lauderdale, Florida, United States, 33308
Pfizer Investigational Site
Merritt Island, Florida, United States, 32952
Pfizer Investigational Site
Rockledge, Florida, United States, 32955
Pfizer Investigational Site
Titusville, Florida, United States, 32796
United States, Georgia
Pfizer Investigational Site
Athens, Georgia, United States, 30607
United States, Illinois
Pfizer Investigational Site
Aurora, Illinois, United States, 60504
United States, Indiana
Pfizer Investigational Site
Goshen, Indiana, United States, 46526
Pfizer Investigational Site
Indianapolis, Indiana, United States, 46260-2082
United States, Iowa
Pfizer Investigational Site
Council Bluffs, Iowa, United States, 51503
United States, Louisiana
Pfizer Investigational Site
Baton Rouge, Louisiana, United States, 70809
Pfizer Investigational Site
Lafayette, Louisiana, United States, 70503
United States, Maryland
Pfizer Investigational Site
Bethesda, Maryland, United States, 20817
United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48106
Pfizer Investigational Site
Troy, Michigan, United States, 48085
United States, Mississippi
Pfizer Investigational Site
Columbus, Mississippi, United States, 39705
Pfizer Investigational Site
Corinth, Mississippi, United States, 38834
Pfizer Investigational Site
Tupelo, Mississippi, United States, 38801
United States, Missouri
Pfizer Investigational Site
St. Louis, Missouri, United States, 63110
Pfizer Investigational Site
St. Peters, Missouri, United States, 63376
United States, Nebraska
Pfizer Investigational Site
Omaha, Nebraska, United States, 68105
United States, Nevada
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89106
Pfizer Investigational Site
Las Vegas, Nevada, United States, 89102
United States, New York
Pfizer Investigational Site
Jamaica, New York, United States, 11432
United States, Oklahoma
Pfizer Investigational Site
Norman, Oklahoma, United States, 73071
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73120
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73109
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States, 73102
Pfizer Investigational Site
Tulsa, Oklahoma, United States, 74136
Pfizer Investigational Site
Tulsa, Oklahoma, United States, 74104
Pfizer Investigational Site
Tulsa, Oklahoma, United States, 74014
United States, Pennsylvania
Pfizer Investigational Site
Lancaster, Pennsylvania, United States, 17605
United States, Tennessee
Pfizer Investigational Site
Knoxville, Tennessee, United States, 37920
United States, Texas
Pfizer Investigational Site
Beaumont, Texas, United States, 77701
Pfizer Investigational Site
Dallas, Texas, United States, 75231
Pfizer Investigational Site
Grapevine, Texas, United States, 76051
Pfizer Investigational Site
Irving, Texas, United States, 75063
United States, Utah
Pfizer Investigational Site
Bountiful, Utah, United States, 84010
Pfizer Investigational Site
Layton, Utah, United States, 84041
Pfizer Investigational Site
Murray, Utah, United States, 84157
Pfizer Investigational Site
Provo, Utah, United States, 84604
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84106
Pfizer Investigational Site
Salt Lake City, Utah, United States, 84102
Pfizer Investigational Site
Sandy, Utah, United States, 84094
Pfizer Investigational Site
West Valley, Utah, United States, 84102
United States, Washington
Pfizer Investigational Site
Kennewick, Washington, United States, 99336
Argentina
Pfizer Investigational Site
Buenos Aires, Capital Federal, Argentina, C1122AAL
Pfizer Investigational Site
Ciudad Autonoma de Buenos Aires, Capital Federal, Argentina, C1094AAD
Pfizer Investigational Site
Buenos Aires, Argentina, C1034ACO
Pfizer Investigational Site
Cordoba, Argentina, 5000
Austria
Pfizer Investigational Site
Grimmenstein, Austria, A-2840
Pfizer Investigational Site
Innsbruck, Austria, A-6020
Pfizer Investigational Site
Linz, Austria, A-4010
Belgium
Pfizer Investigational Site
Bruxelles, Belgium, 1070
Pfizer Investigational Site
Leuven, Belgium, 3000
Pfizer Investigational Site
Liege, Belgium, 4000
Brazil
Pfizer Investigational Site
Rio de Janeiro, RJ, Brazil, 20231 -050
Pfizer Investigational Site
Rio de Janeiro, RJ, Brazil, 20230-130
Pfizer Investigational Site
Porto Alegre, RS, Brazil, 90840-440
Pfizer Investigational Site
Barretos, SP, Brazil, 14784-400
Pfizer Investigational Site
Sao Paulo, SP, Brazil, 01308-050
Canada, Ontario
Pfizer Investigational Site
Kingston, Ontario, Canada, K7L 5P9
Pfizer Investigational Site
Kingston, Ontario, Canada, K7L 2V7
Pfizer Investigational Site
Oshawa, Ontario, Canada, L1G 2B9
Pfizer Investigational Site
Toronto, Ontario, Canada, M4N 3M5
Pfizer Investigational Site
Toronto, Ontario, Canada, M5G 2M9
Canada, Quebec
Pfizer Investigational Site
Greenfield Park, Quebec, Canada, J4V 2H1
Pfizer Investigational Site
Levis, Quebec, Canada, G6V 3Z1
Pfizer Investigational Site
Rimouski, Quebec, Canada, G5L 5T1
Canada, Saskatchewan
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada, S7N 4H4
Canada
Pfizer Investigational Site
Quebec, Canada, G1J 1Z4
Chile
Pfizer Investigational Site
Independencia, Santiago, RM, Chile, 8380456
Pfizer Investigational Site
Providencia, Santiago, RM, Chile, 7500921
Pfizer Investigational Site
Santiago, Chile
Colombia
Pfizer Investigational Site
Medellin, Antioquia, Colombia, 0
Pfizer Investigational Site
Medellin, Antioquia, Colombia
Czech Republic
Pfizer Investigational Site
Ceske Budejovice, Czech Republic, 370 87
Pfizer Investigational Site
Nova Ves pod Plesi, Czech Republic, 262 04
Pfizer Investigational Site
Olomouc, Czech Republic, 775 20
Pfizer Investigational Site
Ostrava-Poruba, Czech Republic, 708 52
Pfizer Investigational Site
Praha 2, Czech Republic, 128 08
Pfizer Investigational Site
Praha 8, Czech Republic, 180 81
Pfizer Investigational Site
Pribram V, Czech Republic, 261 95
Pfizer Investigational Site
Tabor, Czech Republic, 390 03
Pfizer Investigational Site
Usti nad Labem, Czech Republic, 401 13
Denmark
Pfizer Investigational Site
Herlev, Denmark, 2730
Pfizer Investigational Site
Hilleroed, Denmark, 3400
Pfizer Investigational Site
Koebenhavn OE, Denmark, 2100
Pfizer Investigational Site
Odense, Denmark, 5000
Germany
Pfizer Investigational Site
Bad Berka, Germany, 99437
Pfizer Investigational Site
Berlin, Germany, 12203
Pfizer Investigational Site
Dresden, Germany, 01307
Pfizer Investigational Site
Ebensfeld, Germany, 96250
Pfizer Investigational Site
Essen, Germany, 45122
Pfizer Investigational Site
Gauting, Germany, 82131
Pfizer Investigational Site
Grosshansdorf, Germany, 22927
Pfizer Investigational Site
Halle (Saale), Germany, 06120
Pfizer Investigational Site
Heidelberg, Germany, 69126
Pfizer Investigational Site
Homburg, Germany, 66424
Pfizer Investigational Site
Mainz, Germany, 55131
Pfizer Investigational Site
Tuebingen, Germany, 72076
Pfizer Investigational Site
Wiesbaden, Germany, 65199
Greece
Pfizer Investigational Site
Heraklion, Crete, Greece, 71 110
Pfizer Investigational Site
Alexandroupoli, Greece, 68100
Pfizer Investigational Site
Athens, Greece, 11527
Pfizer Investigational Site
Kifisia, Athens, Greece, 145 64
Hong Kong
Pfizer Investigational Site
Kowloon, Hong Kong
Pfizer Investigational Site
Shatin, NT, Hong Kong
Pfizer Investigational Site
Tuen Mun,, Hong Kong
Hungary
Pfizer Investigational Site
Budapest, Hungary, H-1529
Pfizer Investigational Site
Deszk, Hungary, 6772
Pfizer Investigational Site
Gyula, Hungary, 5703
Pfizer Investigational Site
Matrahaza, Hungary, H-3233
Pfizer Investigational Site
Szekesfehervar, Hungary, 8000
Pfizer Investigational Site
Zalaegerszeg-Pozva, Hungary, H-8900
Italy
Pfizer Investigational Site
Catania, Italy, 95122
Pfizer Investigational Site
Grosseto, Italy, 58100
Pfizer Investigational Site
Mantova, Italy, 46100
Pfizer Investigational Site
Milano, Italy, 20132
Pfizer Investigational Site
Milano, Italy, 20162
Pfizer Investigational Site
Monza (MI), Italy, 20052
Pfizer Investigational Site
Novara, Italy, 28100
Pfizer Investigational Site
Orbassano (TO), Italy, 10043
Pfizer Investigational Site
Parma, Italy, 43100
Pfizer Investigational Site
Roma, Italy, 00152
Pfizer Investigational Site
Rozzano (MI), Italy, 20089
Korea, Republic of
Pfizer Investigational Site
Seoul, Korea, Republic of, 138-736
Pfizer Investigational Site
Seoul, Korea, Republic of, 120-725
Pfizer Investigational Site
Seoul, Korea, Republic of, 135-710
Pfizer Investigational Site
Seoul, Korea, Republic of, 120-752
Netherlands
Pfizer Investigational Site
Enschede, Ov, Netherlands, 7513 ER
Pfizer Investigational Site
's-Hertogenbosch, Netherlands, 5211 RW
Pfizer Investigational Site
Amsterdam, Netherlands, 1081 HV
Pfizer Investigational Site
Arnhem, Netherlands, 6815 AD
Pfizer Investigational Site
Harderwijk, Netherlands, 3844 DG
Pfizer Investigational Site
Maastricht, Netherlands, 6229 HX
Pfizer Investigational Site
Rotterdam, Netherlands, 3075 EA
Pfizer Investigational Site
Rotterdam, Netherlands, 3097 DZ
Norway
Pfizer Investigational Site
Kristiansand S, Norway, 4604
Pfizer Investigational Site
Oslo, Norway, 0379
Pfizer Investigational Site
Stavanger, Norway, 4011
Pfizer Investigational Site
Tromso, Norway, 9038
Pfizer Investigational Site
Trondheim, Norway, 7030
Poland
Pfizer Investigational Site
Lodz, Poland, 93-509
Pfizer Investigational Site
Opole, Poland, 45-060
Pfizer Investigational Site
Otwock, Poland, 05-400
Pfizer Investigational Site
Warszawa, Poland, 02-781
Pfizer Investigational Site
Warszawa, Poland, 01-138
Pfizer Investigational Site
Zielona Gora, Poland, 65-046
Russian Federation
Pfizer Investigational Site
Moscow, Russian Federation, 143423
Pfizer Investigational Site
Moscow, Russian Federation, 115478
Pfizer Investigational Site
St-Petersburg, Russian Federation, 194044
Pfizer Investigational Site
St. Petersburg, Russian Federation, 197022
Slovakia
Pfizer Investigational Site
Bratislava, Slovakia, 826 06
Pfizer Investigational Site
Kosice, Slovakia, 041 90
Pfizer Investigational Site
Kvetnica pri Poprade, Slovakia, 058 87
Pfizer Investigational Site
Nitra-Zobor, Slovakia, 949 88
Pfizer Investigational Site
Zilina, Slovakia, 012 07
Spain
Pfizer Investigational Site
Sabadell, Barcelona, Spain, 08208
Pfizer Investigational Site
Palma de Mallorca, Islas Baleares, Spain, 07198
Pfizer Investigational Site
La Laguna, Santa Cruz de Tenerife, Spain, 38320
Pfizer Investigational Site
Dos Hermanas, Sevilla, Spain, 41700
Pfizer Investigational Site
Barcelona, Spain, 08036
Pfizer Investigational Site
La Coruña, Spain, 15006
Pfizer Investigational Site
Madrid, Spain, 28046
Pfizer Investigational Site
Malaga, Spain, 29010
Pfizer Investigational Site
Sevilla, Spain, 41013
Pfizer Investigational Site
Valencia, Spain, 46015
Switzerland
Pfizer Investigational Site
Genolier, Switzerland, 1272
Taiwan
Pfizer Investigational Site
Gwei Shan Township, Taoyuan County, Taiwan, 333
Pfizer Investigational Site
Taichung, Taiwan, 40705
Pfizer Investigational Site
Tainan, Taiwan, 704
Thailand
Pfizer Investigational Site
Pathumwan, Bangkok, Thailand, 10330
Pfizer Investigational Site
Amphoe Mueang, Chiang Mai, Thailand, 50200
Pfizer Investigational Site
Bangkok, Thailand, 10700
United Kingdom
Pfizer Investigational Site
Bebington, Wirral, United Kingdom, CH63 4JY
Pfizer Investigational Site
Cambridge, United Kingdom, CB2 0QQ
Pfizer Investigational Site
Derby, United Kingdom, DE1 2QY
Pfizer Investigational Site
Dundee, United Kingdom, DD1 9SY
Pfizer Investigational Site
Keighley, West Yorkshire, United Kingdom, BD20 6TD
Pfizer Investigational Site
London, United Kingdom, NW3 2QG
Pfizer Investigational Site
London, United Kingdom, NW1 2PG
Pfizer Investigational Site
Peterborough, United Kingdom, PE3 6DA
Pfizer Investigational Site
Rhyl, Denbigshire, United Kingdom, LL18 5UJ
Pfizer Investigational Site
Sheffield, United Kingdom, S10 2SJ
Pfizer Investigational Site
Southampton, United Kingdom, SO16 6YD
Pfizer Investigational Site
Yeovil, Somerset, United Kingdom, BA21 4AT
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00457392     History of Changes
Other Study ID Numbers: A6181087, SUN1087
Study First Received: April 4, 2007
Results First Received: July 6, 2011
Last Updated: September 24, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Pfizer:
Non-small cell lung cancer
sunitinib
erlotinib
Phase 3

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Erlotinib
Sunitinib
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors

ClinicalTrials.gov processed this record on July 22, 2014